Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
出版年份 2021 全文链接
标题
Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 19, Pages 10822
出版商
MDPI AG
发表日期
2021-10-08
DOI
10.3390/ijms221910822
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
- (2021) Narjes Nasiri-Ansari et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis
- (2021) Shimaa K. Elkazzaz et al. LIFE SCIENCES
- Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells
- (2021) Nawel Zaibi et al. PLoS One
- Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
- (2021) Christian Hölscher BRITISH JOURNAL OF PHARMACOLOGY
- Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
- (2021) Sin-Hee Park et al. Cardiovascular Diabetology
- Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
- (2021) Kana N. Miyata et al. CLINICAL SCIENCE
- Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials
- (2021) Jonathan J. H. Bray et al. DIABETES OBESITY & METABOLISM
- A sweet spot for macrophages: Focusing on polarization
- (2021) Depeng Yang et al. PHARMACOLOGICAL RESEARCH
- Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
- (2021) Zien Zhou et al. STROKE
- Mechanism and application of metformin in kidney diseases: An update
- (2021) Anni Song et al. BIOMEDICINE & PHARMACOTHERAPY
- SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction
- (2021) Ahmed S. Ahmed et al. BIOMEDICINE & PHARMACOTHERAPY
- Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease
- (2021) Ferdinando Carlo Sasso et al. Cardiovascular Diabetology
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- The role of incretins and incretin-based drugs in autoimmune diseases
- (2021) Shabnam Radbakhsh et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment
- (2021) Yaoyun Niu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Non-Coding RNAs in Kidney Diseases: The Long and Short of Them
- (2021) Juan Antonio Moreno et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
- (2021) Giuseppe Palmiero et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats
- (2021) Jingjing Tian et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Empagliflozin and neohesperidin mitigate methotrexate hepatotoxicity via Nrf2/PPARγ/HO-1 signalling initiation and suppression of NF-κB/Keap1/HSP70/caspase-3 axis in rats
- (2021) Adel T. Osman et al. LIFE SCIENCES
- Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
- (2021) Francesco Prattichizzo et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study
- (2021) Diana Nabrdalik-Leśniak et al. Oxidative Medicine and Cellular Longevity
- Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
- (2021) Nami Lee et al. Journal of Immunology Research
- Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
- (2021) Sanjay Kalra et al. Diabetes Therapy
- Safety of Semaglutide
- (2021) Mark M. Smits et al. Frontiers in Endocrinology
- Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
- (2021) Jing Xu et al. Cells
- Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
- (2021) Nunzia D'Onofrio et al. Molecular Metabolism
- Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors
- (2020) Milton Packer AMERICAN JOURNAL OF NEPHROLOGY
- Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
- (2020) Nikole J. Byrne et al. Circulation-Heart Failure
- Interplay of adenosine monophosphate‐activated protein kinase/sirtuin‐1 activation and sodium influx inhibition mediates the renal benefits of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: A novel conceptual framework
- (2020) Milton Packer DIABETES OBESITY & METABOLISM
- Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation
- (2020) Shu Fang et al. Journal of Diabetes Research
- Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs
- (2020) Milton Packer Cardiovascular Diabetology
- Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
- (2020) Detmar Kolijn et al. CARDIOVASCULAR RESEARCH
- Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
- (2020) Xiaodong Sun et al. DIABETES
- Recent advances in understanding the role of hypoxia-inducible factor 1α in renal fibrosis
- (2020) Xuejiao Wei et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease
- (2020) Mehmet Kanbay et al. JOURNAL OF NEPHROLOGY
- Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors
- (2020) Milton Packer JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Guidelines and definitions for research on epithelial–mesenchymal transition
- (2020) Jing Yang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Stimulation of GLP-1 Receptor Inhibits Methylglyoxal-Induced Mitochondrial Dysfunctions in H9c2 Cardiomyoblasts: Potential Role of Epac/PI3K/Akt Pathway
- (2020) Narawat Nuamnaichati et al. Frontiers in Pharmacology
- A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress
- (2020) Jonathan J.H. Bray et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
- (2020) Chintan N. Koyani et al. PHARMACOLOGICAL RESEARCH
- Empagliflozin suppresses inflammation and protects against acute septic renal injury
- (2020) Zaid H. Maayah et al. INFLAMMOPHARMACOLOGY
- Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha
- (2020) Angelamellisy Ndibalema et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
- (2020) Masaomi Nangaku et al. Kidney International Reports
- Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
- (2020) Laween Uthman et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors
- (2020) Milton Packer Circulation-Heart Failure
- Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials
- (2020) Victor Okunrintemi et al. DIABETES OBESITY & METABOLISM
- Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver
- (2020) Mohammed Kh. ElMahdy et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
- (2020) Niki Katsiki et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats
- (2020) Rania G. Abdel-latif et al. LIFE SCIENCES
- Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-κB/Nrf-2/PPAR-γ interplay in mice
- (2020) Amir Mohamed Abdelhamid et al. LIFE SCIENCES
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways
- (2020) Raquibul Hasan et al. Scientific Reports
- Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK–Akt–eNOS pathway in the isoprenaline-induced oxidative stress model
- (2020) Raquibul Hasan et al. Scientific Reports
- New Insights Into the Role and Mechanism of Partial Epithelial-Mesenchymal Transition in Kidney Fibrosis
- (2020) Lili Sheng et al. Frontiers in Physiology
- Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis
- (2020) Riying Liang et al. Endocrine Connections
- Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
- (2020) Brent A McLean et al. ENDOCRINE REVIEWS
- NRF2 in Cardiovascular Diseases: a Ray of Hope!
- (2020) Ruju Vashi et al. Journal of Cardiovascular Translational Research
- Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
- (2020) Amelia Charlton et al. Biology-Basel
- Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
- (2020) John J.V. McMurray et al. CIRCULATION
- microRNA-665 silencing improves cardiac function in rats with heart failure through activation of the cAMP signaling pathway
- (2019) Bin Lin et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Endothelial to Mesenchymal Transition in Cardiovascular Disease
- (2019) Jason C. Kovacic et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
- (2019) Hiroe Nagaike et al. Diabetes Therapy
- Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
- (2019) Ajay Sood et al. Metabolic Syndrome and Related Disorders
- Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart
- (2019) Wei Ding et al. Frontiers in Endocrinology
- Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
- (2019) Keiichiro Matoba et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Liraglutide attenuates pre-established atherosclerosis in apolipoprotein E deficient mice via regulation of immune cell phenotypes and pro-inflammatory mediators
- (2019) Robyn Bruen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling
- (2019) Fengjuan Huang et al. Frontiers in Endocrinology
- Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice
- (2019) Tzu-Hsien Tsai et al. Cells
- Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca2+ channel
- (2019) Linjing Huang et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage
- (2019) Humberto Reyes-Pardo et al. BMC Nephrology
- The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus
- (2019) Weiling Leng et al. Annals of Translational Medicine
- Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation
- (2019) Foteini Moschovaki Filippidou et al. AMERICAN JOURNAL OF PATHOLOGY
- Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
- (2019) Liang Xu et al. BMJ Open Diabetes Research & Care
- Simultaneous angiotensin receptor blockade and glucagon‐like peptide‐1 receptor activation ameliorate albuminuria in obese insulin‐resistant rats
- (2019) Ruben Rodriguez et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition
- (2019) Nitin A. Das et al. CELLULAR SIGNALLING
- Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
- (2018) Radica Z. Alicic et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes
- (2018) Yochai Birnbaum et al. CARDIOVASCULAR DRUGS AND THERAPY
- The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis
- (2018) Ya-Kun Li et al. PHARMACOLOGICAL RESEARCH
- Glucagon-Like Peptide-1 and its Cleavage Products are Renoprotective in Murine Diabetic Nephropathy
- (2018) Moellmann Julia et al. DIABETES
- MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer
- (2018) Xiaotian Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
- (2017) Leon A Adams et al. GUT
- Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
- (2017) Mohsen Mazidi et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat
- (2017) Ya Zhang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
- (2017) Jui-Ting Chang et al. BMC Pharmacology & Toxicology
- Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway
- (2017) Anping Wang et al. PLoS One
- GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway
- (2016) Qin He et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1
- (2016) Fen Xu et al. DIABETOLOGIA
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Warburg Effect: How Does it Benefit Cancer Cells?
- (2016) Maria V. Liberti et al. TRENDS IN BIOCHEMICAL SCIENCES
- Partial Epithelial-to-Mesenchymal Transition and Other New Mechanisms of Kidney Fibrosis
- (2016) Sara Lovisa et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice
- (2015) Serap Sancar-Bas et al. GROWTH FACTORS
- Unknown
- (2015) Fei Yan et al. MOLECULAR MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress
- (2015) Antonio Ceriello et al. Therapeutics and Clinical Risk Management
- Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes
- (2014) Antonio Ceriello et al. DIABETES CARE
- Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes
- (2013) A. Ceriello et al. DIABETES CARE
- Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
- (2013) Andrew E. Hogan et al. DIABETOLOGIA
- Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
- (2013) Yen-Ta Chen et al. Journal of Translational Medicine
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes
- (2013) Lan He et al. Journal of Diabetes Investigation
- Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
- (2012) Daisuke Shiraishi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
- (2012) Hari Hendarto et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Exenatide Exerts a Potent Antiinflammatory Effect
- (2011) Ajay Chaudhuri et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
- (2010) I. Hadjiyanni et al. DIABETOLOGIA
- Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression
- (2009) Le Thi Kim Chung et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search